Overview

Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2028-12-31

Target enrollment:

Participant gender:

Summary

This is a prospective, multicenter, randomized, double-blind, placebo-controlled study. The main purpose of the study is to evaluate the clinical efficacy and safety of Nimotuzumab combined with nab-paclitaxel plus gemcitabine (AG) in the perioperative treatment of high-risk resectable/borderline resectable pancreatic cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Biotech Pharmaceutical Co., Ltd.

Collaborators:

Peking University Cancer Hospital & Institute
The First Affiliated Hospital with Nanjing Medical University

Treatments:

nimotuzumab